From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer– insights from the national cancer institute
Abstract Background Triple-negative breast cancer (TNBC) is characterized by its aggressive behavior and limited treatment options, primarily due to the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TROP-2, a transmembr...
Saved in:
| Main Authors: | Noura A. A. Ebrahim, Mustafa A. Hussein, Mohamed Emam Sobeih, Nancy H. Amin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14402-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers
by: William Jacot, et al.
Published: (2025-03-01) -
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
by: Rebecca Dent, et al.
Published: (2025-03-01) -
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
by: Lijuan Weng, et al.
Published: (2024-03-01) -
Exploring the clinicopathological parameters of HER2 low breast cancers: insights from a retrospective cohort study
by: Sana Ahuja, et al.
Published: (2024-12-01) -
Evaluation of Trop 2 expression in thyroid lesions
by: Vani D, et al.
Published: (2025-03-01)